S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
66,000% upside on tiny biotech? (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Laser breakthrough could send stock soaring 2,467% (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
66,000% upside on tiny biotech? (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Laser breakthrough could send stock soaring 2,467% (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
66,000% upside on tiny biotech? (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Laser breakthrough could send stock soaring 2,467% (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
66,000% upside on tiny biotech? (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Laser breakthrough could send stock soaring 2,467% (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
NASDAQ:AFMD

Affimed (AFMD) Stock Forecast, Price & News

$0.71
+0.01 (+1.43%)
(As of 06/9/2023 ET)
Compare
Today's Range
$0.65
$0.73
50-Day Range
$0.67
$1.08
52-Week Range
$0.55
$3.40
Volume
1.27 million shs
Average Volume
1.02 million shs
Market Capitalization
$106.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Affimed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
674.8% Upside
$5.50 Price Target
Short Interest
Healthy
3.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
-0.40mentions of Affimed in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.80) to ($0.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

225th out of 987 stocks

Pharmaceutical Preparations Industry

100th out of 466 stocks


AFMD stock logo

About Affimed (NASDAQ:AFMD) Stock

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Stock News Headlines

America's Worst Nightmare: A Major Financial Crisis Looms
Something strange is happening in our financial system. UBS analysts predict over 50,000 retail locations may close soon. Retail giants like Walmart, Foot Locker, Bed Bath & Beyond, and Macy's are already downsizing their stores. Are you using the best technology to protect your money at all costs?
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Affimed (NASDAQ: AFMD)
Analyst Ratings for Affimed
Berenberg Bank Reaffirms Their Buy Rating on Affimed (AFMD)
What Wall Street expects from Affimed's earnings
Affimed's Earnings Outlook
Affimed Q1 2023 Earnings Preview
Affimed (NASDAQ:AFMD) Sees Large Decline in Short Interest
See More Headlines

AFMD Price History

AFMD Company Calendar

Last Earnings
3/23/2023
Today
6/09/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFMD
Employees
197
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+674.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-90,610,000.00
Net Margins
-271.06%
Pretax Margin
-272.30%

Debt

Sales & Book Value

Annual Sales
$43.58 million
Book Value
$1.31 per share

Miscellaneous

Free Float
143,664,000
Market Cap
$106.02 million
Optionable
Optionable
Beta
2.53

Key Executives

  • Adolf Hoess
    Chief Executive Officer
  • Wolfgang Fischer
    Chief Operating Officer
  • Angus W. Smith
    Chief Financial Officer
  • Andreas Harstrick
    Chief Medical Officer
  • Arndt Schottelius
    Chief Scientific Officer













AFMD Stock - Frequently Asked Questions

Should I buy or sell Affimed stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings
or view top-rated stocks.

What is Affimed's stock price forecast for 2023?

6 Wall Street research analysts have issued twelve-month target prices for Affimed's shares. Their AFMD share price forecasts range from $1.00 to $8.00. On average, they expect the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 674.8% from the stock's current price.
View analysts price targets for AFMD
or view top-rated stocks among Wall Street analysts.

How have AFMD shares performed in 2023?

Affimed's stock was trading at $1.24 at the beginning of 2023. Since then, AFMD stock has decreased by 42.8% and is now trading at $0.7099.
View the best growth stocks for 2023 here
.

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our AFMD earnings forecast
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) issued its earnings results on Thursday, March, 23rd. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03. The biopharmaceutical company earned $11.39 million during the quarter, compared to analysts' expectations of $7.82 million. Affimed had a negative trailing twelve-month return on equity of 61.94% and a negative net margin of 271.06%.

What ETFs hold Affimed's stock?

ETFs with the largest weight of Affimed (NASDAQ:AFMD) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ALPS Medical Breakthroughs ETF (SBIO).

What other stocks do shareholders of Affimed own?
What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.50%), State Street Corp (1.69%), Geode Capital Management LLC (0.96%), Renaissance Technologies LLC (0.94%), Acadian Asset Management LLC (0.83%) and Two Sigma Investments LP (0.60%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $0.71.

How much money does Affimed make?

Affimed (NASDAQ:AFMD) has a market capitalization of $106.02 million and generates $43.58 million in revenue each year. The biopharmaceutical company earns $-90,610,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does Affimed have?

The company employs 197 workers across the globe.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.

This page (NASDAQ:AFMD) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -